Please select the option that best describes you:

After completing 6 cycles of docetaxel plus ADT for metastatic hormone-sensitive prostate cancer per CHAARTED, are there clinical scenarios in which you would add an additional AR targeted agent (ex: enzalutamide, abiraterone, or apalutamide) to ADT?   

Does post docetaxel PSA influence your decision?



Answer from: Medical Oncologist at Academic Institution
Comments
Medical Oncologist at Sweetwater Regional Medical Center
Would you do that if they had failed these drugs (...
Sign in or Register to read more